FDA Approves Merck's KEYTRUDA® (pembrolizumab) in ...



glaucoma laser surgery :: Article Creator

The Media And I: Eye Surgery At The VA

Lars, not a veteran himself, expressed his strong support for veterans and his desire to see them receive the best care during their military service and thereafter. He alluded to a past Veterans Administration (VA) initiative that attempted to have the government itself manufacture eyeglasses for veterans, which ultimately proved inefficient and costly compared to private sector alternatives.

The VA is now proposing that optometrists, instead of ophthalmologists, perform certain kinds of delicate eye surgery. I have strong reservations about this proposal, beginning with the vast difference in expertise between ophthalmologists (eye surgeons) and optometrists, who typically fit glasses and contact lenses. More specifically, concerns over optometrists' surgical proficiency, which is best achieved through lengthy training, a high volume of operations, and the impracticality of allowing optometrists to perform complex eye surgery.

Our discussion highlights concern about the VA's quality of healthcare and the importance of considering private-sector options to ensure that veterans receive the best possible care without compromising their well-being.

You can find the audio of our conversation here, and my article on the subject, "Not Seeing Clearly," here. 


Mass Eye And Ear Researchers Create Possible Glaucoma Treatment Strategy To Direct Stem Cells To Retina

In the study, researchers changed the microenvironment in the eye in a way that enabled them to take stem cells from blood and turn them into retinal ganglion cells that were capable of migrating and surviving into the eye's retina.

Image credit: ©Catalin – stock.Adobe.Com

Glaucoma is one of the leading causes of blindness globally, and the loss of vision due to the loss of retinal ganglion cells (RGCs) currently cannot be reversed with any treatment.

Several studies have looked at replacing RGCs through cell transplants, but this process is still in the research and development stage and fraught with limitations that highlight a need for a more precise manner of effectively repopulating these cells in the retina.1 Now, a multidisciplinary team led by researchers at the Schepens Eye Research Institute of Mass Eye and Ear has identified a new strategy for glaucoma cell replacement therapy.

In the study,1 researchers changed the microenvironment in the eye in a way that enabled them to take stem cells from blood and turn them into retinal ganglion cells that were capable of migrating and surviving into the eye's retina. The researchers conducted their study on the adult mouse retina, but the work's implications could one day be applied to human retina, according to the study.

According to a Mass Eye and Ear news release, a current limitation that impedes the success of current stem cell transplantation strategies in retina studies is that the majority of donor cells remain at the site of injection and do not migrate where they are most needed.2 To identify an improved solution, the researchers created RGCs out of stem cells, then tested the ability of various signaling molecules known as chemokines to guide these new neurons to their correct positions within the retina.

The researchers used a "big data" approach and examined hundreds of such molecules and receptors to find 12 unique to RGCs. They found stromal-derived factor 1 was the best-performing molecule for both migration and transplantation.

"This method of using chemokines to guide donor cell movement and integration represents a promising approach to restoring vision in glaucoma patients," senior author Petr Baranov, MD, PhD, of Mass Eye and Ear, who is also an assistant professor of Ophthalmology at Harvard Medical School, said in the news release."It was an exciting journey to work with a team of talented scientists with unique expertise to develop novel techniques in this study to modify the local environment to guide cell behavior – techniques that potentially be applied to treat other neurodegenerative conditions."

According to the Mass Eye and Ear news release, the co-led by members of Baranov's lab at Mass Eye and Ear including bioengineer and lead study author Jonathan R Soucy, PhD, and lead bioinformatician Emil Kriukov, MD. Co-authors also included Levi Todd, Monichan Phay, Volha V. Malechka, John Dayron Rivera and Thomas A Reh.

The study received funding from several National Eye Institute (NEI) of the National Institutes of Health (NIH) grants, with a complete list available in the paper, as well as grants from the Bright Focus Foundation and Gilbert Family Foundation.1

Further, the University of Washington disclosed a patent incorporating the endogenous reprogramming technology described in this report with inventors LT and TAR.2

References 1. Baranov, Petr; Soucy, Jonathan; Todd, Levi; Kruukov, Emil. Controlling donor and newborn neuron migration and maturation in the eye through microenvironment engineering. Cell Biology. Published November 6, 2023. Accessed November 17, 2023. DOI: 10.1073/pnas.2302089120 2. Mass Eye and Ear researchers develop potential glaucoma treatment strategy to guide stem cells to the retina. EurekAlert! Accessed November 18, 2023. Https://www.Eurekalert.Org/news-releases/1008522

Global Glaucoma Surgery Devices Market To Reach $2.27 Billion By 2030, Driven By Rising Burden Of Glaucoma And Minimally Invasive Procedures

Company Logo

Global Glaucoma Surgery Devices Market

Global Glaucoma Surgery Devices Market

Dublin, Oct. 31, 2023 (GLOBE NEWSWIRE) -- The "Glaucoma Surgery Devices Market Size, Share & Trends Analysis Report By Product (Laser Systems, Diamond Knives), By Surgery Method (MIGS, Laser Surgery), By End-use (Hospitals, Ophthalmic Clinics), And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.Com's offering.

The global glaucoma surgery devices market is expected to reach USD 2.27 billion by 2030, registering a CAGR of 4.61% from 2023 to 2030.

The rising global burden of glaucoma is expected to contribute to market growth over the forecast period. In addition, government support, such as favorable reimbursement policies and foreign direct investment provisions, is expected to drive market growth, especially in developing regions. Rising demand for Minimally Invasive Glaucoma Surgery (MIGS) procedures is expected to drive the demand for advanced glaucoma surgery devices over the forecast period.

The government and non-profit organizations have launched several campaigns to raise knowledge about glaucoma and the procedures used to treat it. These efforts are expected to help increase the demand for cutting-edge surgical methods. In addition, a shift in consumer preference toward sophisticated minimally invasive surgical procedures is anticipated to positively affect market expansion.

Moreover, the high adoption of surgical treatment over medications for the treatment of glaucoma is expected to boost the market growth in the near future. The traditional way of glaucoma therapy involving topical medications is considered first-line treatment followed by laser surgery.

The development of new procedures, such as MIGS, creates new growth opportunities in the market. According to the National Library of Medicine (NCBI), approximately 40, 000 MIGS surgical procedures were performed in patients diagnosed with glaucoma in 2018. This minimally invasive surgery can reduce hospital stays, lowering the chance of patients contracting hospital-acquired infections. Shorter hospital stays also enable patients to return to their normal lives quicker.

Story continues

Frequent launches of advanced devices are also expected to fuel market growth during the forecast period. For instance, in April 2023, Johnson & Johnson Vision received the U.S. FDA 510 (k) clearance for its ELITA Femtosecond laser for the development of LASIK flaps.

Companies Mentioned

Glaucoma Surgery Devices Market Report Highlights

  • By product, the traditional surgery devices segment dominated the market by capturing a share of over 40% in 2022 owing to the high preference for traditional glaucoma surgery

  • Based on surgery method, the traditional glaucoma surgery segment held the largest market share of 35.11% in 2022 owing to its efficiency

  • The ophthalmic clinics end-use segment is expected to expand at the fastest CAGR of 4.80% over the forecast period attributed to the rising number of patients suffering from ophthalmic and other related disorders

  • North America held the largest share of 37.26% in 2022 and is expected to expand at a healthy CAGR over the forecast period

  • Asia Pacific is expected to be the fastest-growing regional market over the forecast period due to the presence of key players and the increasing prevalence of diabetes

  • Key Attributes:

    Report Attribute

    Details

    No. Of Pages

    188

    Forecast Period

    2022 - 2030

    Estimated Market Value (USD) in 2022

    $1.57 Billion

    Forecasted Market Value (USD) by 2030

    $2.27 Billion

    Compound Annual Growth Rate

    4.6%

    Regions Covered

    Global

    Key Topics Covered:

    Chapter 1. Methodology and Scope

    Chapter 2. Executive Summary

    Chapter 3. Glaucoma Surgery Devices Market Variables, Trends & Scope3.1. Market Lineage Outlook3.1.1. Parent market outlook3.1.2. Related/ancillary market outlook3.2. Penetration & Growth Prospect Mapping3.3. Industry Value Chain Analysis3.3.1. Reimbursement framework3.4. Market Dynamics3.4.1. Market driver analysis3.4.1.1. Rising geriatric population3.4.1.2. Growing adoption of surgical treatments for glaucoma3.4.1.3. Rising number of government and non-government glaucoma care initiatives3.4.1.4. Growing prevalence of diabetes3.4.2. Market restraint analysis3.4.2.1. Availability of alternative treatment methods3.4.2.2. Lack of awareness about glaucoma and its treatment procedures in underdeveloped countries3.5. Glaucoma Surgery Devices Market Analysis Tools

    Chapter 4. Glaucoma Surgery Devices Market: Product Estimates & Trend Analysis

    Chapter 5. Glaucoma Surgery Devices Market: Surgery Method Estimates & Trend Analysis

    Chapter 6. Glaucoma Surgery Devices Market: End-use Estimates & Trend Analysis

    Chapter 7. Glaucoma Surgery Devices Market: Regional Estimates & Trend Analysis

    Chapter 8. Competitive Landscape

    For more information about this report visit https://www.Researchandmarkets.Com/r/aev6qh

    About ResearchAndMarkets.ComResearchAndMarkets.Com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

    Attachment

    CONTACT: CONTACT: ResearchAndMarkets.Com Laura Wood,Senior Press Manager press@researchandmarkets.Com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900




    Comments

    Popular posts from this blog

    Uveitis Eye Inflammation Causes, Symptoms & Treatment

    Robert Zakar gives back to community

    Goopy Eyes: Causes and Treatment